A single-center, prospective, observational study on the effectiveness and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma in real-world clinical settings First published 24/11/2022 Last updated 23/04/2024 EU PAS number:EUPAS49571 Study Finalised